Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | BRS3 | P32247 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | WDR5 | P61964 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.43 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.43 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.43 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.43 |
| ▸ | ATP4A | P20648 | 2/20 | 0.43 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.43 |
| ▸ | ATP4B | P51164 | 2/20 | 0.43 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.43 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.43 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21029237 | 1.00 | KMT2A (0.45) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL14344286 | 1.00 | KMT2A (0.45) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL12021142 | 0.92 | BRS3 (0.46) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL13019030 | 0.91 | AGXT (0.38) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL3386628 | 0.89 | KMT2A (0.44) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL18710710 | 0.89 | KMT2A (0.44) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL3386622 | 0.89 | KMT2A (0.44) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| Omeprazole Magnesium SCHEMBL30206693 | 0.88 | KMT2A (0.46) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL29474363 | 0.88 | KMT2A (0.43) | KMT2AMEN1BRS3ALDH1A1WDR5 | |
| SCHEMBL7844981 | 0.87 | KMT2A (0.43) | KMT2AMEN1BRS3ALDH1A1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112255352-B | Method for detecting related substances of esomeprazole sodium for injection | 海南卫康制药(潜山)有限公司 | 2022-10-14 | — | — | CN | claimed |
| WO-2011140446-A2 | PHARMACEUTICAL FORMULATIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-11-10 | — | — | WO | claimed |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11903935-B2 | Inhibitors of SARM1 NADase activity and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-02-20 | — | — | US | disclosed |
| CN-112229920-B | Method for detecting potential genotoxic impurities of esomeprazole sodium | 海南中玉药业有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-112255352-B | Method for detecting related substances of esomeprazole sodium for injection | 海南卫康制药(潜山)有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11253503-B2 | Inhibitors of SARM1 NADase activity and uses thereof | WASHINGTON UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| US-11253503-B2 | Inhibitors of SARM1 NADase activity and uses thereof | WASHINGTON UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220040164-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20200129493-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-04-30 | — | — | US | disclosed |
| WO-2018057989-A1 | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20110293713-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NSAID AND PROTON PUMP INHIBITOR DRUGS | DR. REDDY'S LABORATORIES, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110293713-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NSAID AND PROTON PUMP INHIBITOR DRUGS | DR. REDDY'S LABORATORIES, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110293713-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NSAID AND PROTON PUMP INHIBITOR DRUGS | DR. REDDY'S LABORATORIES, INC. | 2011-12-01 | — | — | US | disclosed |
| WO-2011140446-A2 | PHARMACEUTICAL FORMULATIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-11-10 | — | — | WO | disclosed |
| EP-2345408-A2 | Acid labile drug formulations | Dr. Reddy's Laboratories Ltd. (IN) | 2011-07-20 | — | — | EP | disclosed |
| US-20070293682-A1 | Methods of Preparing Sulfinamides and Sulfoxides | APSINTERM, LLC | 2007-12-20 | — | — | US | disclosed |
| US-7256297-B2 | Methods of preparing sulfinamides and sulfoxides | APSINTERM, LLC. (US) | 2007-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903935-B2 | Inhibitors of SARM1 NADase activity and uses thereof | SARM1, NADK, NNMT | KMT2A 2098/4885MEN1 3371/4885BRS3 4538/4885 |
| US-20070293682-A1 | Methods of Preparing Sulfinamides and Sulfoxides | STS, TST, CBS | KMT2A 1066/4885MEN1 1917/4885BRS3 2544/4885 |
| US-20200129493-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | SARM1, NADK, NNMT | KMT2A 2098/4885MEN1 3371/4885BRS3 4538/4885 |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | SARM1, NADK, NNMT | KMT2A 2098/4885MEN1 3371/4885BRS3 4538/4885 |
| US-20220040164-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | SARM1, NADK, NNMT | KMT2A 2098/4885MEN1 3371/4885BRS3 4538/4885 |
| US-20110293713-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NSAID AND PROTON PUMP INHIBITOR DRUGS | PGA5, HPGD, NNT | KMT2A 4457/4885MEN1 4429/4885BRS3 404/4885 |
| US-11253503-B2 | Inhibitors of SARM1 NADase activity and uses thereof | SARM1, NADK, NNMT | KMT2A 2098/4885MEN1 3371/4885BRS3 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.